Sep 17, 2025 8:15am EDT bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025
Sep 09, 2025 8:00am EDT Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules
Sep 03, 2025 8:00am EDT U.S. Medicine Magazine Spotlights CyPath® Lung as Promising Tool to Improve Lung Cancer Detection in Veterans, Lower Costs to the VA
Aug 14, 2025 4:15pm EDT bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
Aug 13, 2025 9:25am EDT bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
Aug 13, 2025 8:00am EDT bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Sales
Jul 29, 2025 8:00am EDT Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient With Inconclusive Imaging and Low-Risk Serum Test Results
Jul 23, 2025 8:00am EDT Case Study: CyPath® Lung Detects Neuroendocrine Tumor Missed by Other Diagnostic Tools
